Shots:

• AbbVie will develop a cystic fibrosis transmembrane conductance regulator (CFTR) potentiator licensed from CF foundation and advance it into clinical development to be used in combination treatment for CF
• The focus of the agreement is to identify new therapeutic options for people with CF by utilizing the clinical expertise to advance the SoC in CF
• AbbVie is currently investigating the combination of potentiator and corrector molecules- targeting CFTR to improve outcomes for people with CF

Click here to­ read full press release/ article | Ref: AbbVie | Image: AbbVie